Radioactive pharmaceuticals, once administered, follow distinct absorption, distribution, metabolism, and excretion (ADME) pathways that must be thoroughly characterized to ensure both patient safety and environmental protection. Protheragen offers integrated preclinical excretion and environmental safety assessment services designed to generate robust, regulatory-compliant data for your radiopharmaceutical development programs.
Radiopharmaceutical excretion studies are a cornerstone of preclinical drug development, providing essential data on how radioactive compounds are cleared from the body. These investigations typically involve mass balance studies using radiolabeled isotopes such as carbon-14 (14C) or tritium (3H), enabling quantitative recovery of administered radioactivity from urine, feces, bile, and expired air over defined collection periods. The resulting data elucidate primary clearance mechanisms—whether renal, hepatobiliary, or pulmonary—and support the calculation of critical pharmacokinetic parameters including elimination half-life and total body clearance.
Fig 1. Study Design of the accelerator mass spectrometry (AMS)-Enabled Human absorption, distribution, metabolism, and excretion (ADME) study. (Spracklin, Douglas K., et al., 2020)
Beyond individual patient safety, the environmental implications of radiopharmaceutical use have garnered increasing regulatory attention. Following administration, a significant fraction of the administered dose is excreted into wastewater systems, potentially introducing short-lived radionuclides such as technetium-99m, iodine-131, fluorine-18, and lutetium-177 into municipal sewage and surface waters. Environmental safety assessments therefore evaluate the fate, transport, and potential ecological impact of these discharges, ensuring compliance with guidelines established by the International Commission on Radiological Protection (ICRP) and regional regulatory bodies.
Protheragen delivers end-to-end preclinical radiopharmaceutical excretion and environmental safety services, combining GLP-compliant ADME studies with comprehensive environmental risk assessments. Our integrated approach ensures that your radiopharmaceutical candidates are characterized with scientific rigor from initial pharmacokinetic profiling through regulatory submission, accelerating your path from bench to bedside while maintaining the highest standards of radiation safety and environmental stewardship.
Quantitative recovery of administered radioactivity from urine, feces, bile, and expired air using 14C, 3H, or 125I labeling to determine primary elimination pathways and mass balance closure.
High-resolution tissue distribution mapping to visualize and quantify compound-related radioactivity across organs, supporting dosimetry calculations and off-target tissue exposure assessments.
Bile duct–cannulated animal studies to characterize hepatobiliary clearance, evaluate enterohepatic recirculation, and quantify fecal excretion components.
LC-MS coupled with radioactive detection (β-RAM) to identify and quantify radiolabeled metabolites in plasma, urine, and feces, elucidating biotransformation pathways.
Preclinical organ dose extrapolation and occupational/public exposure risk evaluation based on biodistribution and excretion kinetics.
Protocol development, in-life study conduct, audit-ready report compilation, and regulatory defense for IND, IMPD, and NDA submissions.
The evaluation of radiopharmaceutical excretion and environmental safety follows a systematic, phased approach that integrates pharmacokinetic characterization with environmental risk mitigation. Each phase is designed to build upon preceding data, ensuring a comprehensive dataset that satisfies both scientific and regulatory expectations.
Ready to advance your radiopharmaceutical program with confidence? Contact us today to discuss your preclinical excretion and environmental safety requirements. Our team of specialists is prepared to design a customized study plan that aligns with your regulatory timeline and scientific objectives—reach out to us and let Protheragen be your trusted partner in radiopharmaceutical development.
Reference